In it’s second year, FemHealth Integrates 2026 is a unique event addressing the gender gap in healthcare – both in health outcomes and within the health industry workforce. Tackling both decades-long inequalities and the emerging field of FemTech, FemHealth Integrates is the perfect opportunity for people of all genders to come together to bring about greater equality in biotech and healthcare.
Theramex
Vice President - Governmental Affairs & Policy
Tina has over 25 years’ experience in global senior leadership roles in the pharmaceutical industry.
She brings experience of launching innovative products across a diverse range of therapy areas within both large and small pharmaceutical companies.
Tina joined Theramex to lead the UK Women’s Health business in July 2020 as General Manager, and in 2025 was appointed as Theramex’s Vice President Europe for Government and Policy, in menopause.
During her tenure as leader of the business for the UK and Ireland, Theramex has brought to market new treatments for menopause, uterine fibroids and endometriosis, while maintaining a leading position for hormone replacement therapy (HRT), as part of a portfolio that also includes fertility and osteoporosis.
As a leading voice in debates on the topic, Tina is a successful campaigner for women’s health, with a track record of advocating on behalf of women, for improvements in policy and practice.
Tina’s contribution has been recognised with a Sunday Times profile, as well as regularly being called on for media appearances, across print, broadcast and online national and trade outlets.
As a member of the government’s Menopause Advisory Group and the Menopause Mandate, Tina supports the development of practical policy solutions to improve the care and wellbeing of perimenopausal women.
In 2024, Tina co-ordinated a landmark report into inequalities of access to HRT and called for greater support for women’s health hubs in the NHS, which was subsequently recognised in a parliamentary committee.
Most recently the long-term campaigning of Tina and others secured an important change in policy, with a new commitment to include the menopause in health checks for women aged 40 and over.
Brain+
Chief Executive Officer
Executive business leader with experience spanning the healthcare, life sciences and investment sectors.
Award winning executive healthtech leader, including Forbes 30 under 30.
Specialist in digital health, including a successful exit as Founder and CEO in 2019. Her expertise is particularly strong within sales and commercialization of innovative healthtech solutions to the care sector.
MSc. in Public Health from Imperial College London.
Tuune
Founder
I’m the founder & CEO of Tuune. My path into healthtech wasn’t linear, I originally studied architecture, urban design and real estate before moving into Health Technology & Management and Endocrinology, but that mix is exactly what shaped how I think today: I’m obsessed with systems, how they fail people, and how we redesign them around real human outcomes.
Tuune provides UK-regulated clinical decision-support software that can assess and identify hormonal conditions and generate the most appropriate, fully personalised treatment and prescribing pathway for each patient.
Liverpool Women's NHS Foundation Trust
Consultant Gynaecologist and Subspecialist in Reproductive Medicine
Dr Katerina Bambang is a Consultant Gynaecologist and Subspecialist in Reproductive Medicine. She is the founder of The Delphi Clinic, a specialist IVF practice providing personalised, integrative fertility care. Her work combines advanced reproductive medicine with integrative systems-based approaches to support fertility and IVF.
She has been Clinical Lead of one of the largest NHS IVF units in the UK at Hewitt Fertility Centre, Liverpool and a Consultant at Alder Hey Children’s Hospital. At Alder Hey, she was lead for fertility preservation for children and adolescents. She has over 20 years’ experience in women’s health, with particular expertise in infertility, recurrent miscarriage, and adolescent gynaecology.
The Daughters of Mars
Founder & Chief Executive Officer
The Daughters of Mars was founded by Lucy Hope, whose background is in textile innovation and functional materials development, with years spent working with natural fibres and health-focused coatings.
Despite millions of tampons being used every month, they are not legally required to undergo medical-grade safety or biocompatibility testing in the UK or EU. Many tampons on the market contain materials, chemicals and heavy metals linked to potential health concerns, despite being worn internally in one of the body’s most absorbent areas.
That’s not acceptable to us at The Daughters of Mars. So we’re changing it.
Our purpose is to transform menstrual products into proactive healthcare, empowering women to take control of their vaginal and gynaecological health at scale. Lucy leads The Daughters of Mars alongside a team of experts in women’s health, materials science and product safety – including Dr Phillip Hay, global specialist in bacterial vaginosis. Together, we are raising the standard of what menstrual care can and should be.
Bruntwood SciTech
Chief Scientific Officer
As Chief Scientific Officer of Bruntwood SciTech, Kath is a member of the executive management team and brings science and tech insights and expertise to developments, overseeing a number of clusters Kath leads science and tech partnerships with universities, hospital trusts, corporate occupiers, investors and innovation providers. She also leads the Innovation and Growth Team who curate and develop the ecosystem, investment, and scientific support for over 1100 science, technology, and digital businesses across Bruntwood SciTech’s innovation districts and clusters. Kath was formerly Managing Director of Bruntwood SciTech’s Alderley Park campus.
Kath joined Bruntwood SciTech from the Executive Board of the Government’s innovation agency, Innovate UK, where she led the team responsible for growing businesses working in the biomedical, health, agriculture and food sectors, creating and delivering a £800m portfolio of infrastructure, grant and loan investments and creating strategic partnerships with pharma, investors, and global charities. Kath is an elected fellow of the Royal Society of Biology.
Women continue to face persistent barriers to accessing healthcare, from delayed diagnoses and fragmented services to the systemic dismissal of women’s pain and symptoms – revealing unmet needs and opportunities for innovation. How can we drive meaningful change to improve access and credibility, building a healthcare system that truly meets women’s needs?
Kathryn Simpson Consulting Limited
Business Consultant
Kathryn is a respected and successful change leadership expert, with diverse career experience in Europe and North America. She has over 25 years of consulting and line experience with leading organisations (Unilever, Mars, KPMG and GSK). Since 2007 she has been leading her own independent consulting business, primarily working within the Life Sciences sector. By partnering with leaders at all levels within the sector, growth and sustainable success has resulted for the organisations she has worked with. She has recently published a book – “Leading for Change: How to thrive during uncertain times”.
She provides each organisation the approaches they need to meet their unique situation. Tailored approaches are used to develop a consolidated understanding of their environment and the priority challenges they face. This provides the basis for facilitating customised workshops where leaders not only create a desired future, but are ready to move forward and implement their ideas. Working with individual leaders or teams she advises how to bring other stakeholders with them so they achieve success together. These practical and supportive approaches create focus, accountability and collaboration across organisations and their partners. Organisations are left with an increased leadership capability and tangible business results.
Four Points Health
Partner
Aahuti Rai is a healthcare innovation NED, Venture Partner, and advisor who works with organisations across the ecosystem, from health-tech innovators and scale-ups to providers, investors, and associations, to turn digital health and AI solutions into scalable, real-world services. She specialises in ecosystem collaboration, commercialisation and clinical adoption, and has a particular focus on mental health and women’s health innovation, including work with initiatives such as the OLS Mental Health Goals Programme. As Chair/NED at 8foldGovernance, Venture Partner at Conduit Connect, and Founder of the Mental Health Innovation Network UK, she helps organisations align strategy, partnerships, and governance so that impactful technologies can be adopted safely, equitably, and at scale.
ImmunoKey
Chief Executive Officer
Dr Gray Kueberuwa is Chief Executive Officer of ImmunoKey, a UK biotechnology company developing next-generation CAR T-cell therapies for solid tumours, with a lead programme focused on ovarian cancer. He trained at the University of Oxford, holding a Master’s degree in Biochemistry and a PhD in oncolytic virotherapy. Gray has over a decade of experience in T-cell immunotherapy across academia and industry, with a track record spanning translational research, platform development, and early clinical strategy.
Theramex
Vice President - Governmental Affairs & Policy
Tina has over 25 years’ experience in global senior leadership roles in the pharmaceutical industry.
She brings experience of launching innovative products across a diverse range of therapy areas within both large and small pharmaceutical companies.
Tina joined Theramex to lead the UK Women’s Health business in July 2020 as General Manager, and in 2025 was appointed as Theramex’s Vice President Europe for Government and Policy, in menopause.
During her tenure as leader of the business for the UK and Ireland, Theramex has brought to market new treatments for menopause, uterine fibroids and endometriosis, while maintaining a leading position for hormone replacement therapy (HRT), as part of a portfolio that also includes fertility and osteoporosis.
As a leading voice in debates on the topic, Tina is a successful campaigner for women’s health, with a track record of advocating on behalf of women, for improvements in policy and practice.
Tina’s contribution has been recognised with a Sunday Times profile, as well as regularly being called on for media appearances, across print, broadcast and online national and trade outlets.
As a member of the government’s Menopause Advisory Group and the Menopause Mandate, Tina supports the development of practical policy solutions to improve the care and wellbeing of perimenopausal women.
In 2024, Tina co-ordinated a landmark report into inequalities of access to HRT and called for greater support for women’s health hubs in the NHS, which was subsequently recognised in a parliamentary committee.
Most recently the long-term campaigning of Tina and others secured an important change in policy, with a new commitment to include the menopause in health checks for women aged 40 and over.
Investment in women’s health continues to rise, but the journey is far from over. Explore the gains made, the untapped opportunities, and how female investors are shaping the next wave of innovation. What’s next for funding the future of care?
Brain+
Chief Executive Officer
Executive business leader with experience spanning the healthcare, life sciences and investment sectors.
Award winning executive healthtech leader, including Forbes 30 under 30.
Specialist in digital health, including a successful exit as Founder and CEO in 2019. Her expertise is particularly strong within sales and commercialization of innovative healthtech solutions to the care sector.
MSc. in Public Health from Imperial College London.
Peachaus
Founder & Chief Executive Officer
After an extensive career in fashion both here in the UK & Australia I am proud to be launching Peachaus, a lifestyle label with an ethical essence.
Peachaus is at the beginning of a longer journey that’s rooted in positivity. Why shouldn’t a fashion brand be a space for optimism, storytelling, spotlighting other organisations and individuals doing brilliant things? I think it should. We want to collaborate with amazing creatives and with our customers, giving them the opportunity to actively shape the dialogue and artistic direction we take. Ultimately, we want to provide a platform that supports and celebrates people and raises voices of hope.
BoobyBiome
Chief Executive Officer and Co-founder
Lydia is CEO and co-founder of BoobyBiome, a company developing bacterial products for infants from the breast milk microbiome. As a microbiologist, Lydia is passionate about creating solutions in the real world for healthcare and the environment using biotechnology. Lydia has pursued this interest throughout her career; winning the Best Therapeutic prize at the international synthetic biology competition iGEM (2017), through her PhD research at University College London where she has published and presented her work widely from conferences to music festivals (2017-2022) and by winning the UCL Grand Challenges award to set up the first UK infant microbiome conference at the Institute of Child Health, Great Ormond Street hospital (2020). Lydia launched BoobyBiome with her co-founders in 2019 after participating in numerous Start-up accelerators and workshops (including BiotechYES, Imagine IF, PULSE, Panacea Stars). To date, Lydia and the BoobyBiome team have team successfully won four grant awards (from the BBSRC and Innovate UK) and completed a private equity round to carry R&D at the company forward. Keen to share her expertise, Lydia mentors iGEM and BiotechYES teams and also guest lectures to MSc students on Birkbeck University’s Bio-Business course.
Manchester Angels
Director
Joely Irlam is a driven innovator, entrepreneur and angel investor in the life sciences and healthcare sector, with a passion for translating scientific research into clinical and commercial success. She is the Co-founder and Director of SpinXperts Ltd, where she accelerates technology transfer into successful biotech ventures. Previously, as Chief Technical Officer at PBD Biotech, she led the development of a phage-based diagnostic for tuberculosis. Joely is also a BioNow mentor at the University Technical College (UTC) in Liverpool.
Joely also spearheaded ManTRa Diagnostics Ltd, a University of Manchester spin-out company focused on biomarker development for cancer treatment, securing major funding and establishing key industry collaborations. With a strong background in academic research at The University of Manchester, she has contributed to pioneering translational radiobiology projects, clinical trials, and biomarker innovation.
Recognised for her leadership and strategic vision, Joely has received accolades such as the ‘Best New Business’ award at the Alderley Park Accelerator. Her expertise spans R&D, business development, regulatory compliance, and innovation-driven partnerships, making her a key figure in bridging academia and industry for healthcare advancement.
YON E Health
Chief Clinical Officer
Dr Muskaan Bhan is a clinically trained physician and digital health executive specialising in AI-enabled women’s health innovation. She currently serves as Chief Clinical Officer at YON E Health, where she leads clinical strategy, regulatory readiness, and product development for a Class IIa medical device integrating biosensor technology with AI. With experience spanning NHS and multiple early-stage ventures, Dr Bhan has led AI product development, regulatory compliance and investor strategy across women’s health and primary care technologies. Dr Bhan is passionate about translating clinical evidence into scalable, regulator-ready digital health solutions that advance equitable access to women’s healthcare
Today’s femtech is evolving. From temperature-sensing rings that pinpoint ovulation with clinical-level accuracy to AI-assisted ultrasound for earlier detection of pelvic pain conditions, how far can we push tech to finally close the data gap in women’s health? Hear about some of the latest innovations focused on improving women’s health and wellness.
Appleyard Lees
Senior Associate
Rachel is a UK and European patent attorney who helps her clients protect their innovations in the biotechnology and life sciences fields. She draws on her research experience when formulating IP strategies with her clients.
Rachel specialises in drafting and prosecuting patent applications and manages large global patent portfolios. She has significant experience advising universities, spin-outs, SMEs and large multinational corporations on their early-stage technologies.
Rachel’s practice encompasses a wide range of technologies, ranging from cancer therapeutics and DNA technologies to probiotics, biomarkers and molecular biology techniques. Rachel also has significant experience advising on the protection of medical devices and methods of diagnosing and treating disease.
In addition, Rachel has successfully completed a WIPO-run course on the UPOV System of Plant Variety Protection and helps her clients obtain protection for their plant varieties in the UK, EU and further afield.
Rachel graduated from the University of Oxford with a Masters degree in Biochemistry. She then completed her PhD at The Gray Institute for Radiation Oncology and Biology at the University of Oxford, where she studied the role of histone modification in directing the choice of DNA repair mechanism.
Meyva
Founder
Anja Ueland is the founder of Meyva, a FemTech company developing smart, wearable heat solutions designed for women’s bodies, starting with a heated bra for breastfeeding and cyclical mastalgia. Her work brings together lived experience, research and innovation to address breast health, an area that remains widely overlooked despite around 70% of women experiencing breast pain at some point in their lives, often driven by hormonal changes.
Through Meyva, Anja is introducing a new category in women’s health called Thermal Wellness. This approach harnesses the power of warmth and the body’s biological responses, translating them into wearable, comfortable solutions that allow women to regulate their own temperature and comfort in everyday life.
Fertilia AI
Founder
Clara is the founder of Fertilia AI, a platform created from her own personal fertility journey. Having experienced firsthand how overwhelming, confusing and isolating this path can be, she became determined to make things better for others. With a blend of lived experience and a passion for thoughtful innovation, Clara is dedicated to empowering individuals and couples with clearer guidance, compassionate support and accessible information. Through Fertilia AI, she aims to bring comfort, clarity and confidence to anyone navigating fertility care.
Her Holistic Health
Managing Director
Dr Divpreet Sacha (MBChB, MRCGP, DipOccMed) is a UK GP and founder of Her Holistic Health, a clinician-led education platform supporting women to navigate fertility and hormonal health with calm, evidence-informed decision support. With additional training in occupational medicine, Divpreet is interested in how real-world constraints, including time, work, access, and data quality, shape women’s health outcomes. Drawing on both clinical practice and lived experience of fertility care (including PCOS, endometriosis, and IVF), Divpreet speaks on bridging the gap between innovation and implementation, and how femtech can support clearer, more person-centred choices without overpromising.
Liverpool Women's NHS Foundation Trust
Consultant Gynaecologist and Subspecialist in Reproductive Medicine
Dr Katerina Bambang is a Consultant Gynaecologist and Subspecialist in Reproductive Medicine. She is the founder of The Delphi Clinic, a specialist IVF practice providing personalised, integrative fertility care. Her work combines advanced reproductive medicine with integrative systems-based approaches to support fertility and IVF.
She has been Clinical Lead of one of the largest NHS IVF units in the UK at Hewitt Fertility Centre, Liverpool and a Consultant at Alder Hey Children’s Hospital. At Alder Hey, she was lead for fertility preservation for children and adolescents. She has over 20 years’ experience in women’s health, with particular expertise in infertility, recurrent miscarriage, and adolescent gynaecology.
The Daughters of Mars
Founder & Chief Executive Officer
The Daughters of Mars was founded by Lucy Hope, whose background is in textile innovation and functional materials development, with years spent working with natural fibres and health-focused coatings.
Despite millions of tampons being used every month, they are not legally required to undergo medical-grade safety or biocompatibility testing in the UK or EU. Many tampons on the market contain materials, chemicals and heavy metals linked to potential health concerns, despite being worn internally in one of the body’s most absorbent areas.
That’s not acceptable to us at The Daughters of Mars. So we’re changing it.
Our purpose is to transform menstrual products into proactive healthcare, empowering women to take control of their vaginal and gynaecological health at scale. Lucy leads The Daughters of Mars alongside a team of experts in women’s health, materials science and product safety – including Dr Phillip Hay, global specialist in bacterial vaginosis. Together, we are raising the standard of what menstrual care can and should be.
Step inside Citylabs 4.0, Bruntwood SciTech’s new £42m world-class development at the heart of one of the UK’s largest NHS Trusts. Join us for an exclusive tour to explore our sustainable Grade A lab and office spaces, and discover how our unique campus ecosystem provides the direct NHS access and talent pipeline needed to scale the future of healthcare.
Please get in touch to book into a tour.
If women aren’t adequately represented in clinical trials, how can we generate evidence that truly reflects women’s health? And can we really claim the science works for them? This session explores the structural barriers and real-world challenges, including how we can redesign clinical trials to drive equity, inclusion, and better outcomes in women’s health.
MD Healthcare
Patient Engagement Pioneer
Mark brings over 30 years of clinician, management consultant and patient perspectives to the healthcare, life sciences and digital health sectors. Working in the NHS, The King’s Fund, the BBC, and as a Founder of the Patient Information Forum, Mark endeavours to make healthcare more person-centric. As the Chief Patient Officer for MD Healthcare, he works with organisations such as AstraZeneca, Diabetes UK, Google Health, JnJ, Macmillan Cancer Support, Microsoft, Pfizer, Novartis & Siemens Healthineers and a wide range of start/ scale-ups to embed patient engagement across the enterprise improve market access and harness digital health. Mark holds, and is exploring, a range of Non-Executive Director and Advisory roles.
OpalMedica
Managing Director
OpalMedica is a MedTech company developing two complementary solutions to accelerate earlier detection of rare and underdiagnosed conditions: KLEOS™ Clinical Flags, a patent-pending Class I medical device, which helps GPs identify potential cases sooner by prompting consideration of rare conditions; and KLEOS™ My Rare Journey, a patient platform for sharing experiences and insights. Together, they inform research and improve outcomes.
PROBr
Co-Founder
Dr. Meghana Nadella is a psychology trainee (UK), clinical pharmacist (India), and health systems innovator working at the intersection of mental health, public health, and social equity. Her work is driven by a commitment to redesigning healthcare for those historically excluded from it, particularly Women, People of colour, LGBTQIA+ communities, and underserved populations. Bridging frontline clinical experience with research, policy engagement, pharmacovigilance, and digital innovation, she develops scalable, culturally intelligent solutions that transform care delivery. Her approach is both deeply human and strategically systemic – combining compassion, data, and design to create lasting impact.
Silvia Health
Founder
Amy Wild is the founder of Silvia Health, a UK based clinician led digital decision support platform focused on menopause care. Silvia brings together guided patient data capture and NICE aligned clinical logic to support clearer, more consistent assessment during perimenopause and menopause within primary care settings.
Amy built Silvia after recognising both lived experience and systemic evidence gaps in women’s health. Her work explores how the way we capture and interpret information at the point of care influences not only clinical decisions, but the quality and representativeness of the data that underpins future research.
Silvia is preparing for NHS pilots and regulatory pathways in 2026.
Clariness
Senior Director Business Development
Kev is a commercial and innovation leader with 15+ years of experience driving growth and digital health solutions across pharma and healthcare. He has built global alliances, engaged NHS systems, and introduced new technologies into complex pathways—transforming partnerships into value‑driven frameworks that deliver revenue growth and set global benchmarks.
Kev is a seasoned commercial and innovation leader with over 15 years of experience in the pharmaceutical and healthcare sectors. He has built a career delivering growth through global alliances, NHS system engagement, and the integration of digital health solutions into complex pathways. Known for transforming partnerships into collaborative, value‑driven frameworks, Kev has driven measurable revenue growth and positioned affiliates as global benchmarks. With a reputation for combining commercial acumen and stakeholder credibility, he is adept at navigating compliance, influencing senior decision‑makers, and translating innovation into sustainable outcomes for patients and businesses alike.
Kev is a commercial and innovation leader with over 15 years of experience delivering growth, partnerships, and digital health solutions across the pharmaceutical and healthcare sectors. His career spans global alliances, NHS system engagement, and the introduction of new technologies into complex healthcare pathways. He has transformed strategic partnerships into collaborative, value‑driven frameworks, driving measurable revenue growth and positioning affiliates as global benchmarks. Recognised for combining commercial acumen with stakeholder credibility, Kev is adept at navigating compliance, influencing senior decision‑makers, and translating innovation into sustainable outcomes for both patients and businesses.
Optum
Director of Business Development
Ceri leads the market launch and commercial strategy for Optum life sciences solutions in the UK. She and her team support life sciences organisations in implementing cutting‑edge technologies that deliver meaningful benefits for healthcare providers, patients, and the NHS. Ceri focuses on enabling research teams to identify emerging health trends, recruit more diverse patient populations into clinical trials and guide patients onto the most appropriate care pathways.
Ceri will join the panel discussing how to redesign clinical trials for greater equity and representation in women’s health — a conversation she is passionate about, as it aligns with her commitment to ensuring evidence generation truly reflects the diversity of real‑world patients.
Step inside Citylabs 4.0, Bruntwood SciTech’s new £42m world-class development at the heart of one of the UK’s largest NHS Trusts. Join us for an exclusive tour to explore our sustainable Grade A lab and office spaces, and discover how our unique campus ecosystem provides the direct NHS access and talent pipeline needed to scale the future of healthcare.
Please get in touch to book into a tour.
Women’s health research is on a reset path to focus on what matters most to women: earlier diagnosis, personalised treatments and a true life‑course view of health. This panel will unpack the RCOG – from endometriosis and menopause-related cognitive change to maternal mental health and the gender gap in drug trials – and ask how to turn them into real-world change.
NIHR HealthTech Research Centre in Accelerated Surgical Care
Co-Director
I have over 15 years experience in leadership roles, developing and implementing strategy as part of research programme grants for the National Institute for Health and Care Research (NIHR) in England. This has included leading change management initiatives, supporting clinical research teams to develop long term strategies to improve on their business development capabilities; as well as improving business processes by making them more efficient and effective, to deliver on goals and objectives.
As a coach and mentor, I help individuals think creatively to come up with long term solutions to their problems and identify new opportunities that support their goals. If I’m not advocating for informed decision making, you can find me spending lots of time volunteering with organisations that support the welfare of children and young people.
Cerebella
Chief Executive Officer & Founder
Nahid Zokaei, PhD, is a cognitive neuroscientist and founder of Cerebella, a digital health platform focused on women’s brain health in midlife and during the menopause transition. With a background spanning academia and industry (Oxford and UCL, and ex-CSO of Brain+), she and her team combine scientific rigour with user-centred design to build personalised, non-drug interventions for brain fog and cognitive change in midlife.
Phase Supplements
Founder
Anna Appleton is the founder of PHASE, a cycle-syncing supplement system designed to provide both nutritional support and practical daily rituals tailored to each phase of a woman’s cycle. Driven by her own experience with severe PMS and PMDD from a young age, Anna set out to create the solution she wished had existed. After finding that traditional medical approaches often masked rather than resolved her symptoms, she began exploring alternative paths. Through extensive self-education, personal research, and collaboration with naturopaths, she discovered the powerful role targeted supplementation and holistic lifestyle changes could play in hormonal wellbeing.
Today, she advocates for better understanding about women’s hormonal health, the importance of living in tune with the body’s natural patterns, and how small, informed changes can have a profound impact on wellbeing.
Adaobi Fertility
Co-Founder
Kwenza is a Registered Nurse with a degree in Sexual Health from the University of Greenwich. She is the co-founder of Adaobi Fertility CIC, an organisation birthed from her lived experience of undergoing IVF treatment with her husband in the UK.
Adaobi Fertility CIC supports the wellbeing of couples diagnosed with infertility, raises community awareness around fertility health, and fundraises to support Hertfordshire couples who are ineligible for NHS-funded IVF treatment.
Deeply passionate about women’s reproductive health and advocating for more equitable reproductive healthcare, Kwenza speaks at women’s events where she highlights the importance of symptom recognition and early diagnosis. Her personal journey through IVF while living with fibroids, fuelled her resolve towards also improving fertility treatment outcomes for women from Black backgrounds.
PrecisionLife
Chief Medical Officer
Dr Véronique Bouchet is Chief Medical Officer at PrecisionLife, an AI-driven precision medicine company that applies advanced combinatorial analytics to uncover the biological drivers of complex chronic diseases. By stratifying patients according to their underlying disease mechanisms, PrecisionLife is helping to predict, treat and prevent complex chronic diseases – creating better, more personalized diagnostic tools and treatment options, with a particular focus on women’s health.
She brings over 30 years of experience across pharma, biotech and digital health, spanning clinical research, licensing, M&A, venture capital and NHS roles.
Previously, she served as Director of Corporate Strategy and Head of Venture Strategy at AstraZeneca and oversaw the creation and $40M financing of spin‑out Albireo Pharma. She has also held several non‑executive roles, including at Stevenage Bioscience Catalyst, International Biotechnology Trust, QMUL and Breast Cancer Now.
A medical doctor with an MBA from INSEAD, Véronique is a recognised leader in precision medicine, women’s health innovation and data‑driven therapeutic development.
Tuune
Founder
I’m the founder & CEO of Tuune. My path into healthtech wasn’t linear, I originally studied architecture, urban design and real estate before moving into Health Technology & Management and Endocrinology, but that mix is exactly what shaped how I think today: I’m obsessed with systems, how they fail people, and how we redesign them around real human outcomes.
Tuune provides UK-regulated clinical decision-support software that can assess and identify hormonal conditions and generate the most appropriate, fully personalised treatment and prescribing pathway for each patient.
Bruntwood SciTech
Head of Innovation and Growth
As Head of Innovation and Growth at Bruntwood SciTech, Hannah supports and grows Manchester’s tech and digital innovation ecosystem, attracting and scaling high-growth businesses, and positioning Manchester as a global hub for innovation
Hannah previously led Innovate Lancashire’s innovation and growth support initiatives as part of Lancashire County Council’s Business Growth Service working across the county to accelerate innovation activity and grow the digital economy.
Prior to moving into innovation and growth, Hannah spent 10 years working in the tech sector across a range of roles including leadership, marketing, product development and business operations. This included leading and growing a EdTech SaaS Scale Up to £3M ARR.
Citylabs 1.0 is part of the Citylabs campus, a world-leading hub for health innovation and precision medicine, located within Manchester University NHS Foundation Trust. It is home to a dynamic cluster of diagnostics, medtech, digital health and genomics businesses that are shaping the future of healthcare. Citylabs offers an ideal environment for companies looking to grow and scale, with direct access to the NHS, a specialist life sciences community, and tailored business support. Companies also benefit from access to over 20,000 STEM graduates each year, creating a strong pipeline of talent to support long-term growth.
Address: Citylabs 1.0, Nelson Street, Manchester, M13 9NQ
Tel: 0161 393 2288
Parking: The closest car park is Grafton Street Car Park (multi-storey). Please use the postcode M13 9WU located off Oxford Road, offering visitor parking with pay-on-foot facilities.
